RIFT Biotherapeutics logo

RIFT Biotherapeutics

Rift, an early stage research and development company, developing first-in-class antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cells microenvironment.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.riftbio.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
6335 Nancy Ridge Drive, Suite R, CA, 92121
San Diego
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/rift-biotherpeutics” connections=”true” suffix=””]

In Mar 2017, SalvaRx investd US$1 Mn in Rift and acquired approx 30% equity in company. Also, Subject to Rift achieving certain development milestones with this initial funding, SalvaRx has the option to invest up to an additional US$1.5 Mn at the same valuation and to acquire all outstanding shares of Rift in exchange for new shares in SalvaRx on the same basis.